Logo

Christopher Bernard

Jul 06, 2016

Curetis has appointed Christopher Bernard as CEO and president of its newly-formed US subsidiary, Curetis USA. He will be responsible for the development of the new subsidiary based in San Diego, CA, and will lead the marketing and sales initiatives for Curetis in the US. Prior to joining Curetis, Bernard served as chief commercial officer of Epic Sciences. Before his work at Epic Sciences, he served as an officer and senior vice president of sales and marketing at Metabolon.

Breaking News
The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.